Aurinia Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Aurinia Pharmaceuticals
AUPH Stock  USD 14.26  0.32  2.19%   
Aurinia Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aurinia Pharmaceuticals' valuation are provided below:
Gross Profit
213.1 M
Profit Margin
0.2928
Market Capitalization
1.9 B
Enterprise Value Revenue
6.5148
Revenue
265.8 M
We have found one hundred twenty available fundamental signals for Aurinia Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Aurinia Pharmaceuticals prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The Aurinia Pharmaceuticals' current Market Cap is estimated to increase to about 1.8 B. The Aurinia Pharmaceuticals' current Enterprise Value is estimated to increase to about 1.5 B

Aurinia Pharmaceuticals Total Revenue

283.92 Million

Check Aurinia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aurinia Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.5 M, Interest Expense of 5.8 M or Selling General Administrative of 190.7 M, as well as many indicators such as Price To Sales Ratio of 4.67, Dividend Yield of 0.0 or PTB Ratio of 3.22. Aurinia financial statements analysis is a perfect complement when working with Aurinia Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Aurinia Stock
Check out the analysis of Aurinia Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

Aurinia Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets664.9 M633.2 M277.7 M
Slightly volatile
Short and Long Term Debt Total95.8 M91.3 M26 M
Slightly volatile
Other Current Liabilities80.3 M76.5 M23.7 M
Slightly volatile
Total Current Liabilities118 M112.4 M34.1 M
Slightly volatile
Property Plant And Equipment Net119.4 M113.7 M28.2 M
Slightly volatile
Current Deferred Revenue13.3 M12.7 M4.1 M
Slightly volatile
Accounts Payable3.2 M6 M3.1 M
Slightly volatile
Non Current Assets Total125.6 M119.7 M40.9 M
Slightly volatile
Cash And Short Term Investments432.9 M412.2 M206.4 M
Slightly volatile
Net Receivables44.1 M42 M10.4 M
Slightly volatile
Common Stock Shares Outstanding176.5 M168.1 M81.7 M
Slightly volatile
Liabilities And Stockholders Equity664.9 M633.2 M277.7 M
Slightly volatile
Non Current Liabilities Total91.1 M86.7 M29.9 M
Slightly volatile
Other Current Assets14.9 M14.2 M6.4 M
Slightly volatile
Other Stockholder Equity61.1 M114.3 M45.2 M
Slightly volatile
Total Liabilities209.1 M199.1 M64 M
Slightly volatile
Property Plant And Equipment Gross122.4 M116.6 M28.8 M
Slightly volatile
Total Current Assets539.3 M513.6 M236.8 M
Slightly volatile
Short Term Debt18.2 M17.3 M5.4 M
Slightly volatile
Intangible Assets6.8 M5 M9.4 M
Pretty Stable
Cash67.3 M95.9 M91.9 M
Slightly volatile
Non Currrent Assets Other899.1 K946.5 K3.8 M
Very volatile
Common Stock1.4 B1.4 B688.4 M
Slightly volatile
Property Plant Equipment8.1 M7.7 M3.4 M
Slightly volatile
Capital Surpluse71.3 M67.9 M35.3 M
Slightly volatile
Non Current Liabilities Other9.2 M12.8 M6.9 M
Slightly volatile
Net Invested Capital357.4 M434.1 M267.7 M
Slightly volatile
Net Working Capital350.6 M401.2 M263 M
Slightly volatile
Capital Stock1.1 B1.4 B793.6 M
Slightly volatile
Capital Lease Obligations95.8 M91.3 M27.8 M
Slightly volatile

Aurinia Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization23.5 M22.4 M5.6 M
Slightly volatile
Selling General Administrative190.7 M181.6 M74.6 M
Slightly volatile
Total Revenue283.9 M270.4 M70.9 M
Slightly volatile
Other Operating Expenses289.6 M275.8 M116.8 M
Slightly volatile
Research Development21.7 M23.9 M26 M
Slightly volatile
Cost Of Revenue34.1 M32.5 M15.4 M
Slightly volatile
Total Operating Expenses255.5 M243.3 M110 M
Slightly volatile
Interest Income20.5 M19.5 M6.9 M
Slightly volatile
Net Interest Income14.7 M14 M4 M
Slightly volatile
Reconciled Depreciation23.5 M22.4 M5.5 M
Slightly volatile
Non Operating Income Net Other818 K476.1 K1.2 M
Slightly volatile
Selling And Marketing Expenses11.3 M12.7 M13.8 M
Slightly volatile

Aurinia Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow61.7 M56.2 M84.6 M
Slightly volatile
Depreciation23.5 M22.4 M5.6 M
Slightly volatile
Capital Expenditures307 K323.1 K738.6 K
Pretty Stable
Stock Based Compensation38.2 M36.3 M15.2 M
Slightly volatile
Cash Flows Other Operating7.1 M4.8 M9.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.674.92552
Very volatile
Days Sales Outstanding68.5651.05113
Very volatile
Average Payables841.8 K886.1 K758.4 K
Slightly volatile
Stock Based Compensation To Revenue0.110.124.736
Pretty Stable
Capex To Depreciation0.01580.01660.4851
Very volatile
EV To Sales4.664.9436
Very volatile
Days Of Inventory On Hand6804563.7 K
Pretty Stable
Payables Turnover5.154.92.1458
Slightly volatile
Sales General And Administrative To Revenue0.730.7713.8238
Pretty Stable
Average Inventory0.790.8325.3 K
Slightly volatile
Research And Ddevelopement To Revenue0.07560.079631.3358
Pretty Stable
Capex To Revenue0.00130.00140.1726
Slightly volatile
Cash Per Share2.742.882.168
Slightly volatile
Days Payables Outstanding57.360.3246.1 K
Slightly volatile
Income Quality7.296.951.9622
Slightly volatile
Intangibles To Total Assets0.00680.00710.2061
Slightly volatile
Current Ratio6.854.118.8424
Pretty Stable
Receivables Turnover9.67.46.5088
Pretty Stable
Graham Number1.241.391.518
Slightly volatile
Capex Per Share0.00210.00230.0425
Slightly volatile
Average Receivables157.7 K166.1 K154.9 K
Slightly volatile
Revenue Per Share1.741.890.7068
Slightly volatile
Interest Debt Per Share0.910.680.2502
Slightly volatile
Debt To Assets0.140.130.0583
Slightly volatile
Days Of Payables Outstanding57.360.3246.1 K
Slightly volatile
Quick Ratio6.723.758.6667
Pretty Stable
Net Income Per E B T1.050.890.9464
Pretty Stable
Cash Ratio0.730.776.0922
Very volatile
Days Of Inventory Outstanding6804563.7 K
Pretty Stable
Days Of Sales Outstanding68.5651.05113
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.421.141.0976
Pretty Stable
Fixed Asset Turnover2.032.1410.4483
Slightly volatile
Debt Ratio0.140.130.0583
Slightly volatile
Price Sales Ratio4.674.92552
Very volatile
Asset Turnover0.520.490.2554
Very volatile

Aurinia Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1.3 B
Slightly volatile
Enterprise Value1.5 B1.4 B1.1 B
Slightly volatile

Aurinia Fundamental Market Drivers

Forward Price Earnings19.7239
Cash And Short Term Investments358.5 M

Aurinia Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aurinia Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Aurinia Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Aurinia Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue12.7 M13.3 M
Total Revenue270.4 M283.9 M
Cost Of Revenue32.5 M34.1 M
Stock Based Compensation To Revenue 0.12  0.11 
Sales General And Administrative To Revenue 0.77  0.73 
Research And Ddevelopement To Revenue 0.08  0.08 
Revenue Per Share 1.89  1.74 
Ebit Per Revenue(0.02)(0.02)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:
How To Invest In Aurinia
Details
Is Aurinia Stock a good investment?
Details
What is Aurinia Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Aurinia Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is there potential for Biotechnology market expansion? Will Aurinia introduce new products? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.3
Earnings Share
0.54
Revenue Per Share
1.941
Quarterly Revenue Growth
0.084
Return On Assets
0.0941
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Aurinia Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aurinia Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Aurinia Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY